1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly’s Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida’s Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m.

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Major depressive disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.

Table Of Contents

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Classification 17
3.3 Symptoms and Subtypes of Major Depressive Disorder 19
3.4 Prognosis 20
3.5 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.1.3 Clinical Practice 23
4.2 Japan 26
5 Competitive Assessment 29
5.1 Overview 29
5.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 31
5.2.1 Lexapro (Escitalopram) 31
5.2.2 Other Selective Serotonin Reuptake Inhibitors 35
5.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 38
5.3.1 Cymbalta (Duloxetine) 38
5.4 Product Profiles: Major Brands, Other Antidepressants 42
5.4.1 Noradrenaline and Specific Serotonergic Antidepressants 42
5.4.2 Tricyclic Antidepressants 45
5.4.3 Brintellix (Vortioxetine) 47
5.5 Product Profiles: Major Brands, Antipsychotics 53
5.5.1 Abilify (Aripiprazole) 53
5.5.2 Seroquel XR (Quetiapine) 57
5.6 Other Therapeutic Classes 61
6 Unmet Needs and Opportunities 62
6.1 Overview 62
6.2 More Effective Pharmacotherapies 63
6.2.1 Unmet Needs 63
6.2.2 Gap Analysis 64
6.2.3 Opportunities 65
6.3 More Favorable Side Effect Profiles 65
6.3.1 Unmet Needs 65
6.3.2 Gap Analysis 66
6.3.3 Opportunities 66
6.4 Rapid Onset of Antidepressant Effects 67
6.4.1 Unmet Needs 67
6.4.2 Gap Analysis 67
6.4.3 Opportunities 67
6.5 Personalized Treatment Approach 68
6.5.1 Unmet Needs 68
6.5.2 Gap Analysis 69
6.5.3 Opportunities 69
7 Pipeline Assessment 70
7.1 Overview 70
7.2 Promising Drugs in Clinical Development 70
7.2.1 Brexpiprazole (OPC-34712) 73
7.2.2 Cariprazine (RGH-188) 79
7.2.3 ALKS-5461 84
7.2.4 Amitifadine (EB-1010) 89
7.2.5 GLYX-13 94
7.2.6 Tedatioxetine (Lu AA24530) 98
7.2.7 ETS6103 102
7.3 Other Drugs in Development 106
8 Market Outlook 108
8.1 Japan 108
8.1.1 Forecast 108
8.1.2 Key Events 111
8.1.3 Drivers and Barriers - Global Issues 111
8.1.4 Drivers and Barriers 113
9 Appendix 116
9.1 Bibliography 116
9.2 Abbreviations 120
9.3 Methodology 124
9.4 Forecasting Methodology 124
9.4.1 Diagnosed MDD Patients 124
9.4.2 Percent of Drug-Treated Patients 124
9.4.3 Drugs Included in Each Therapeutic Class 125
9.4.4 Launch and Patent Expiry Dates 125
9.4.5 General Pricing Assumptions 126
9.4.6 Individual Drug Assumptions 127
9.4.7 Generic Erosion 129
9.4.8 Pricing of Pipeline Agents 130
9.5 Physicians and Specialists Included in this Study 131
9.6 About the Authors 133
9.6.1 Analyst 133
9.6.2 Therapy Area Directors 133
9.6.3 Global Head of Healthcare 134
9.7 About GlobalData 135
9.8 Disclaimer 135

1.1 List of Tables

Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 18
Table 2: Subtypes of Major Depressive Disorder 19
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 21
Table 4: Treatment Guidelines for Major Depressive Disorder 22
Table 5: Most Prescribed Drugs for MDD by Class in Japan, 2013 22
Table 6: Country Profile - Japan 28
Table 7: Leading Treatments for MDD, 2013 30
Table 8: Product Profile - Lexapro 32
Table 9: Safety of Lexapro - Five Most Frequently Reported Adverse Events 34
Table 10: Lexapro SWOT Analysis, 2014 34
Table 11: Relative Frequency of Common Adverse Effects for Different SSRIs 38
Table 12: Product Profile - Cymbalta 39
Table 13: Cymbalta SWOT Analysis, 2023 41
Table 14: Product Profile - Mirtazapine 43
Table 15: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events 44
Table 16: Mirtazapine SWOT Analysis, 2014 45
Table 17: TCAs SWOT Analysis, 2014 47
Table 18: Product Profile - Brintellix 49
Table 19: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials 50
Table 20: Safety of Brintellix - Five Most Frequently Reported Adverse Events 52
Table 21: Brintellix SWOT Analysis, 2014 52
Table 22: Product Profile - Abilify 54
Table 23: Safety of Abilify - Five Most Frequently Reported Adverse Events 56
Table 24: Abilify SWOT Analysis, 2014 56
Table 25: Product Profile - Seroquel XR 58
Table 26: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants 59
Table 27: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events 60
Table 28: Seroquel XR SWOT Analysis, 2014 60
Table 29: Summary of Minor Therapeutic Classes in MDD, 2013 61
Table 30: Unmet Needs and Opportunities in MDD 63
Table 31: Comparison of Therapeutic Classes in Development for MDD, 2013 72
Table 32: Product Profile - Brexpiprazole 75
Table 33: Safety of Brexpiprazole - Most Frequently Reported Adverse Events 77
Table 34: Brexpiprazole SWOT Analysis, 2014 79
Table 35: Product Profile - Cariprazine 81
Table 36: Cariprazine SWOT Analysis, 2014 84
Table 37: Product Profile - ALKS-5461 86
Table 38: ALKS-5461 SWOT Analysis, 2014 89
Table 39: Product Profile - Amitifadine 90
Table 40: Amitifadine SWOT Analysis, 2014 94
Table 41: Product Profile - GLYX-13 95
Table 42: GLYX-13 SWOT Analysis, 2014 98
Table 43: Product Profile - Tedatioxetine 100
Table 44: Tedatioxetine SWOT Analysis, 2014 102
Table 45: Product Profile - ETS6103 103
Table 46: ETS6103 SWOT Analysis, 2014 106
Table 47: Drugs in Development for MDD, 2014 107
Table 48: Sales Forecasts ($m) for MDD in Japan, 2013-2023 109
Table 49: Key Events Impacting Sales for MDD in Japan, 2013-2023 111
Table 50: MDD Market - Drivers and Barriers, 2013-2023 111
Table 51: MDD Market in Japan - Drivers and Barriers, 2013-2013 113
Table 52: Key Launch Dates 125
Table 53: Key Patent Expiries 126
Table 54: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 132

1.2 List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 17
Figure 2: Disease Management Model for Major Depressive Disorder 24
Figure 3: Major Depressive Disorder Treatment Algorithm 26
Figure 4: MDD - Phase IIb-III Pipeline, 2014 71
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023 72
Figure 6: Clinical and Commercial Positioning of Brexpiprazole 78
Figure 7: Clinical and Commercial Positioning of Cariprazine 83
Figure 8: Clinical and Commercial Positioning of ALKS-5461 88
Figure 9: Clinical and Commercial Positioning of Amitifadine 93
Figure 10: Clinical and Commercial Positioning of GLYX-13 97
Figure 11: Clinical and Commercial Positioning of Tedatioxetine 101
Figure 12: Clinical and Commercial Positioning of ETS6103 105
Figure 13: Sales for MDD in Japan by Drug Class, 2013-2023 110

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Depression Partnering 2010 to 2016

Global Depression Partnering 2010 to 2016

  • $ 1495
  • Industry report
  • November 2016
  • by Currentpartnering

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. - ...

 Treatment Resistant Depression-Pipeline Insights, 2016

Treatment Resistant Depression-Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “ Treatment Resistant Depression-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Treatment Resistant ...

Neuromodulation Market (by Technology, Applications Segment, Region and Company) and Forecast to 2021 - Global Analysis

Neuromodulation Market (by Technology, Applications Segment, Region and Company) and Forecast to 2021 - Global Analysis

  • $ 1250
  • Industry report
  • October 2016
  • by Igate Research

The global neuromodulation market is poised to cross US$ 5 Billion mark by 2021. Neuromodulation is a technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Therapy Market in Canada - Forecast

  • December 2016
    63 pages
  • Therapy  

    Monoclonal Anti...  

  • Canada  

View report >

Related Market Segments :

Depression

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.